Standard BioTools Inc. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
Standard BioTools Inc. (LAB) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of -$0.01 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2026-08-05
- Standard BioTools Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2026-06-30 was -$0.01.
- Standard BioTools Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2026-03-31 was $0.37.
- Standard BioTools Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2025-09-30 was -$0.01.
- Standard BioTools Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2025-06-30 was -$0.04.
- Standard BioTools Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2025 was -$0.04.
- Standard BioTools Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2024 was -$0.14.
- Standard BioTools Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2023 was $0.00.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.01 10-Q · filed 2026-08-05 | $0.35 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $0.37 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$0.04 10-K · filed 2026-03-16 | |||
| 2025-09-30 | -$0.01 10-Q · filed 2025-11-04 | -$0.06 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | -$0.04 10-Q · filed 2026-08-05 | -$0.05 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | -$0.01 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$0.14 10-K · filed 2026-03-16 | |||
| 2024-09-30 | -$0.01 10-Q · filed 2025-11-04 | -$0.12 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | -$0.05 10-Q · filed 2025-08-15 | -$0.11 10-Q · filed 2025-08-15 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |